SMITHKLINE BEECHAM CONSUMER HEALTHCARE U.S, SALES ADVANCE 18% IN 1993
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM CONSUMER HEALTHCARE U.S, SALES ADVANCE 18% IN 1993 (at comparable exchange rates), benefiting from continued growth of the Tums antacid line and from the company's OTC partnership with Marion Merrell Dow. Sales for SmithKline Beecham's U.S. consumer healthcare segment, which includes OTC drugs and oral care products, reached $675 mil. (BRITISH POUND)450 for the year, on a (British Pound)1 = $1.50 exchange rate.